Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission

Purinergic Signalling
Filipe NascimentoJ A Ribeiro

Abstract

Amyotrophic lateral sclerosis (ALS) is a disease leading to neuromuscular transmission impairment. A2A adenosine receptor (A2AR) function changes with disease stage, but the role of the A(1) receptors (A1Rs) is unknown and may have a functional cross-talk with A2AR. The role of A1R in the SOD1(G93A) mouse model of ALS in presymptomatic (4-6 weeks old) and symptomatic (12-14 weeks old) phases was investigated by recording endplate potentials (EPPs), miniature endplate potentials (MEPPs), and quantal content (q.c.) of EPPs, from Mg(2+) paralyzed hemidiaphragm preparations. In presymptomatic mice, the A1R agonist, N (6)-cyclopentyladenosine (CPA) (50 nM), decreased mean EPP amplitude, MEPP frequency, and q.c. of EPPs, an effect quantitatively similar to that in age-matched wild-type (WT) mice. However, coactivation of A2AR with CGS 21680 (5 nM) prevented the effects of CPA in WT mice but not in presymptomatic SOD1(G93A) mice, suggestive of A1R/A2AR cross-talk disruption in this phase of ALS. DPCPX (50 nM) impaired CGS 21680 facilitatory action on neuromuscular transmission in WT but not in presymptomatic mice. In symptomatic animals, CPA only inhibited transmission if added in the presence of adenosine deaminase (ADA, 1 U/mL). ADA...Continue Reading

References

Mar 1, 1987·The Journal of Physiology·J A Ribeiro, A M Sebastião
Jan 1, 1996·Progress in Brain Research·J A RibeiroA M Sebastião
Apr 7, 2004·British Journal of Pharmacology·Silvana De LorenzoAdriana Losavio
Feb 17, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Francisco CiruelaRafael Franco
Nov 6, 2007·TheScientificWorldJournal·Sergi FerréRafael Franco
Jun 11, 2009·British Journal of Pharmacology·Ana M Sebastião, Joaquim A Ribeiro
Jul 30, 2009·Handbook of Experimental Pharmacology·Ana M Sebastião, Joaquim A Ribeiro
Oct 1, 2009·The Journal of Pharmacology and Experimental Therapeutics·Paula A PousinhaJoaquim A Ribeiro
Mar 1, 2012·Neurobiology of Aging·Paula A PousinhaJoaquim A Ribeiro
Jan 31, 2013·Journal of Neuroscience Research·Rosa Luisa PotenzaPatrizia Popoli
May 10, 2013·Purinergic Signalling·Sofia Cristóvão-FerreiraAna M Sebastião
May 18, 2013·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Fabrizio VincenziKatia Varani
Jan 31, 2014·International Journal of Molecular Sciences·Sandeep ShethVickram Ramkumar
Oct 15, 2014·Nature Reviews. Neurology·Bart Swinnen, Wim Robberecht

❮ Previous
Next ❯

Citations

Sep 17, 2016·The Journal of Physiology·Danielle ArbourRichard Robitaille
Mar 21, 2017·CNS Neuroscience & Therapeutics·Mahshad Kolahdouzan, Mazen J Hamadeh
Apr 26, 2018·Frontiers in Pharmacology·Ágatha Oliveira-GiacomelliHenning Ulrich
Feb 14, 2019·Neurochemical Research·Monica ArmidaRosa Luisa Potenza
May 2, 2018·Frontiers in Pharmacology·Ana M SebastiãoJoaquim A Ribeiro
Oct 11, 2017·Frontiers in Pharmacology·Geoffrey Burnstock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.